Advertisement

Archives of Gynecology and Obstetrics

, Volume 300, Issue 3, pp 569–573 | Cite as

Macrolide antibiotics roxithromycin vs. azithromycin for preterm premature rupture of membranes: a retrospective comparison

  • Hanoch SchreiberEmail author
  • Pnina Shitrit
  • Gili Man-El
  • Offra Engel
  • Arie Berkovitz
  • Tal Biron-Shental
Maternal-Fetal Medicine
  • 58 Downloads

Abstract

Purpose

Prophylactic antibiotics to prolong latency and reduce the risk of neonatal and maternal infections are used for preterm premature rupture of membranes. This study compared outcomes between two macrolides: roxithromycin given twice a day for a week and azithromycin, given as a single dose, which is more convenient.

Methods

Two local protocols were retrospectively compared: roxithromycin and ampicillin from July 2005 to May 2016, and azithromycin and ampicillin from May 2016 to May 2018. Inclusion criteria were singleton pregnancy, at 24–34 weeks of gestation upon admission with preterm premature rupture of membranes. Primary outcome was length of the latency period, defined as time from first antibiotic dose to 34 + 0 weeks, or spontaneous or indicated delivery prior to 34 + 0 weeks. Secondary outcomes were rates of chorioamnionitis, delivery mode, birth weight and Apgar scores.

Results

A total of 207 women met inclusion criteria, of whom, 173 received penicillin and roxithromycin and 34 received penicillin and azithromycin. Baseline characteristics were similar between groups. The latent period was longer in the azithromycin group than in the roxithromycin group (14.09 ± 14.2 days and 7.87 ± 10.2 days, respectively, P = 0.003). Rates of chorioamnionitis, cesarean deliveries, Apgar scores and birth weights were similar between the groups.

Conclusions

Azithromycin compared to roxithromycin results in a longer latency period in the setting of preterm premature rupture of membranes at 24–34 weeks of gestation. Given its more convenient regimen and our results, it seems justified to use azithromycin as the first-line treatment for patients with preterm premature rupture of membranes.

Keywords

Azithromycin Latency period Preterm premature rupture of membranes Prophylactic antibiotics Roxithromycin 

Notes

Acknowledgements

The authors thank Nava Jelin, MS for data analysis, and Faye Schreiber, MS for editing the manuscript. They are employees of Meir Medical Center.

Author contribution

HS: study conception and design, and manuscript revisions. PS: data collection, data analysis and interpretation, and manuscript writing. GM-E: data collection, data analysis and interpretation, and manuscript writing. OE: data collection, data analysis and interpretation, and manuscript writing. AB: data analysis and interpretation, and manuscript writing. TB-S: study conception and design, and data interpretation.

Funding

This study was not funded.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Meir Medical Center Ethics Committee in March 2018, approval number 0075-18-MMC. All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was not required.

References

  1. 1.
    Mercer BM (2005) Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin N Am 32:411–428CrossRefGoogle Scholar
  2. 2.
    Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD et al (1997) Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. JAMA 278:989–995CrossRefGoogle Scholar
  3. 3.
    Melamed N, Hadar E, Ben-Haroush A, Kaplan B, Yogev Y (2009) Factors affecting the duration of the latency period in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 22(11):1051–1056CrossRefGoogle Scholar
  4. 4.
    Averbuch B, Mazor M, Shoham-Vardi I, Chaim W, Vardi H, Horowitz S, Shuster M (1995) Intra-uterine infection in women with preterm premature rupture of membranes: maternal and neonatal characteristics. Eur J Obstet Gynecol Reprod Biol 62:25–29CrossRefGoogle Scholar
  5. 5.
    Rocha FG, Slavin TP, Li D, Tiirikainen MI, Bryant-Greenwood GD (2013) Genetic associations of relaxin: preterm birth and premature rupture of fetal membranes. Am J Obstet Gynecol 209(258):e1–8Google Scholar
  6. 6.
    French JI, McGregor JA (1996) The pathobiology of premature rupture of membranes. Semin Perinatol 20:344–368CrossRefGoogle Scholar
  7. 7.
    Practice Bulletin No. 172: Premature rupture of membranes (2016) American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. Obstet Gynecol 128:e165–e177.  https://doi.org/10.1097/AOG.0000000000001712 CrossRefGoogle Scholar
  8. 8.
    Kenyon S, Boulvain M, Neilson JP (2013) Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 12:CD001058.  https://doi.org/10.1002/14651858.CD001058.pub3 Google Scholar
  9. 9.
    Daskalakis G, Goya M, Pergialiotis V et al (2019) Prevention of spontaneous preterm birth. Arch Gynecol Obstet 299:1261–1273.  https://doi.org/10.1007/s00404-019-05095-y CrossRefGoogle Scholar
  10. 10.
    Park JW, Park KH, Kook SY et al (2019) Immune biomarkers in maternal plasma to identify histologic chorioamnionitis in women with preterm labor. Arch Gynecol Obstet 299:725–732.  https://doi.org/10.1007/s00404-019-05061-8 CrossRefGoogle Scholar
  11. 11.
    Blumer JL (2005) Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int J Antimicrob Agents 26(Suppl 3):S143–S147CrossRefGoogle Scholar
  12. 12.
    Yonath A (2005) Antibiotics targeting ribosomes: resistance, selectivity, synergism, and cellular regulation. Annu Rev Biochem 74:649–679CrossRefGoogle Scholar
  13. 13.
    Yudin MH, van Schalkwyk J, Van Eyk N (2017) No. 233-Antibiotic therapy in preterm premature rupture of the membranes. J Obstet Gynaecol Can 39:e207–e212.  https://doi.org/10.1016/j.jogc.2017.06.003 CrossRefGoogle Scholar
  14. 14.
    Dale PO, Tanbo T, Bendvold E, Moe N (1989) Duration of the latency period in preterm premature rupture of the membranes. Maternal and neonatal consequences of expectant management. Eur J Obstet Gynecol Reprod Biol 30:257–262CrossRefGoogle Scholar
  15. 15.
    Goya M, Bernabeu A, García N, Plata J, Gonzalez F, Merced C, Llurba E, Suy A, Casellas M, Carreras E, Cabero L (2013) Premature rupture of membranes before 34 weeks managed expectantly: maternal and perinatal outcomes in singletons. J Matern Neonatal Med. 26:290–293CrossRefGoogle Scholar
  16. 16.
    Zuckerman JM (2004) Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin N Am 18:621–649CrossRefGoogle Scholar
  17. 17.
    Pierson RC, Gordon SS, Haas DM (2014) A retrospective comparison of antibiotic regimens for preterm premature rupture of membranes. Obstet Gynecol 124:515–519CrossRefGoogle Scholar
  18. 18.
    Puri SK, Lassman HB (1987) Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother 20(suppl B):89–100CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyMeir Medical CenterKfar SabaIsrael
  2. 2.Infectious Disease UnitMeir Medical CenterKfar SabaIsrael
  3. 3.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations